Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

29 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
GBR 830, an anti-OX40, improves skin gene signatures and clinical scores in patients with atopic dermatitis.
Guttman-Yassky E, Pavel AB, Zhou L, Estrada YD, Zhang N, Xu H, Peng X, Wen HC, Govas P, Gudi G, Ca V, Fang H, Salhi Y, Back J, Reddy V, Bissonnette R, Maari C, Grossman F, Wolff G. Guttman-Yassky E, et al. Among authors: gudi g. J Allergy Clin Immunol. 2019 Aug;144(2):482-493.e7. doi: 10.1016/j.jaci.2018.11.053. Epub 2019 Feb 6. J Allergy Clin Immunol. 2019. PMID: 30738171 Free article. Clinical Trial.
Randomized, double-blind, placebo-controlled trial of ISC 17536, an oral inhibitor of transient receptor potential ankyrin 1, in patients with painful diabetic peripheral neuropathy: impact of preserved small nerve fiber function.
Jain SM, Balamurugan R, Tandon M, Mozaffarian N, Gudi G, Salhi Y, Holland R, Freeman R, Baron R. Jain SM, et al. Among authors: gudi g. Pain. 2022 Jun 1;163(6):e738-e747. doi: 10.1097/j.pain.0000000000002470. Epub 2021 Sep 2. Pain. 2022. PMID: 34490850 Free PMC article. Clinical Trial.
Phase 2b randomized trial of OX40 inhibitor telazorlimab for moderate-to-severe atopic dermatitis.
Rewerska B, Sher LD, Alpizar S, Pauser S, Pulka G, Mozaffarian N, Salhi Y, Martinet C, Jabert W, Gudi G, Ca V, Gn S, Macoin J, Anstett V, Turrini R, Doucey MA, Blein S, Konto C, Machkova M. Rewerska B, et al. Among authors: gudi g. J Allergy Clin Immunol Glob. 2023 Nov 22;3(1):100195. doi: 10.1016/j.jacig.2023.100195. eCollection 2024 Feb. J Allergy Clin Immunol Glob. 2023. PMID: 38187863 Free PMC article.
An Open-Label, Single-Period, Two-Stage, Single Oral Dose Pharmacokinetic Study of Remogliflozin Etabonate Tablet 100 and 250 mg in Healthy Asian Indian Male Subjects Under Fasting and Fed Conditions.
Joshi S, Gudi G, Menon VCA, Tandon M, Joshi V, Suryawanshi S, Barkate H, Sawant N, Katare S, Siddique W. Joshi S, et al. Among authors: gudi g. Clin Pharmacokinet. 2020 Mar;59(3):349-357. doi: 10.1007/s40262-019-00819-4. Clin Pharmacokinet. 2020. PMID: 31583610 Clinical Trial.
Discovery of 5-(2-chloro-4'-(1H-imidazol-1-yl)-[1,1'-biphenyl]-4-yl)-1H-tetrazole as potent and orally efficacious S-nitrosoglutathione reductase (GSNOR) inhibitors for the potential treatment of COPD.
Muthukaman N, Deshmukh S, Tondlekar S, Tambe M, Pisal D, Sarode N, Mhatre S, Chakraborti S, Shah D, Bhosale VM, Kulkarni A, Mahat MYA, Jadhav SB, Gudi GS, Khairatkar-Joshi N, Gharat LA. Muthukaman N, et al. Among authors: gudi gs. Bioorg Med Chem Lett. 2018 Dec 15;28(23-24):3766-3773. doi: 10.1016/j.bmcl.2018.10.012. Epub 2018 Oct 10. Bioorg Med Chem Lett. 2018. PMID: 30340896
29 results